LC
CASC

Landaas & Company’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Landaas & Company’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-33
Closed – – 348
2017
Q4 		$0 Hold
33
– – ﹤0.01% 376
2017
Q3 		$0 Buy
+33
New +$126 ﹤0.01% 353

Landaas & Company's CASC Position: Q1 2018 in Review

Landaas & Company sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 33 shares.

Landaas & Company first reported a position in CASC in Q3 2017 and held it in 2 quarters. The position peaked at $0 in Q4 2017. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.

  • Landaas & Company reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Landaas & Company sold 33 Cascadian Therapeutics, Inc. shares in Q1 2018.
  • Landaas & Company first reported a position in Cascadian Therapeutics, Inc. in Q3 2017 and held it in 2 quarters.
  • Landaas & Company's Cascadian Therapeutics, Inc. position peaked at $0 in Q4 2017.
  • 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.

Based on Landaas & Company's 13F filing for Q1 2018, filed 14 May 2018.